deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03239223

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)

Sponsor: Antiva Biosciences

Conditions CIN Cervical Cancer Cervical Dysplasia Cervical Intraepithelial Neoplasia Cervical Neoplasm HSIL HSIL of Cervix High-Grade Squamous Intraepithelial Lesions High-grade Cervical Intraepithelial Neoplasia Human Papilloma Virus
Interventions ABI-1968
Updated 14 times since 2017 Last updated: Jul 8, 2019 Started: Jan 1, 2018 Primary completion: Oct 30, 2018 Completion: Oct 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates CIN and Cervical Cancer and is currently completed. Antiva Biosciences leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2019 — Aug 2019 [monthly]

    Completed PHASE1

▶ Show 9 earlier versions

  1. Dec 2018 — Jan 2019 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  5. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  7. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Oct 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE1

  9. Aug 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Antiva Biosciences
Data source: Antiva Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations